AS Latvijas Juras medicinas centrs Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

AS Latvijas Juras medicinas centrs hat ein Gesamteigenkapital von €6.2M und eine Gesamtverschuldung von €0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €9.1M bzw. €2.9M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

€0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€827.13k
Eigenkapital	€6.15m
Gesamtverbindlichkeiten	€2.92m
Gesamtvermögen	€9.07m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: LJM1RDie kurzfristigen Aktiva des Unternehmens (€1.4M) decken seine kurzfristigen Passiva (€1.6M) nicht.

Langfristige Verbindlichkeiten: LJM1RDie kurzfristigen Vermögenswerte des Unternehmens (€1.4M) übersteigen seine langfristigen Verbindlichkeiten (€1.4M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: LJM1R ist schuldenfrei.

Schulden abbauen: LJM1R hatte vor 5 Jahren keine Schulden.

Schuldendeckung: LJM1R hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: LJM1R hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

AS Latvijas Juras medicinas centrs Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Third quarter 2024 earnings released: €0.029 loss per share (vs €0.35 profit in 3Q 2023)

AS Latvijas Juras medicinas centrs Appoints S. Zadorožnijs as Member of the Board

Second quarter 2024 earnings released: €0.15 loss per share (vs €0.082 loss in 2Q 2023)

New major risk - Revenue and earnings growth

AS Latvijas Juras medicinas centrs, Annual General Meeting, Jun 12, 2024

AS Latvijas Juras Medicinas Centrs Announces Resignation of Anatolijs Ahmetovs from the Management Board

Full year 2023 earnings released: €0.018 loss per share (vs €0.69 profit in FY 2022)

Investor sentiment deteriorates as stock falls 21%

Third quarter 2023 earnings released: EPS: €0.35 (vs €0.068 in 3Q 2022)

Upcoming dividend of €0.10 per share at 0.9% yield

Second quarter 2023 earnings released: €0.082 loss per share (vs €0.11 loss in 2Q 2022)

AS Latvijas Juras Medicinas Centrs Announces Dividend Payment, Payable December 1, 2023

First quarter 2023 earnings released: €0.17 loss per share (vs €0.47 profit in 1Q 2022)

AS Latvijas Juras medicinas centrs, Annual General Meeting, Jun 13, 2023

AS Latvijas Juras medicinas centrs to Report Nine Months, 2023 Results on Nov 20, 2023

Third quarter 2022 earnings released: EPS: €0.068 (vs €0.36 in 3Q 2021)

Second quarter 2022 earnings released: €0.11 loss per share (vs €0.16 profit in 2Q 2021)

AS Latvijas Juras medicinas centrs to Pay Dividend, Payable on June 28, 2022

Upcoming dividend of €0.20 per share

First quarter 2022 earnings released: EPS: €0.47 (vs €0.25 in 1Q 2021)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: EPS €0.16 (vs €0.098 in 2Q 2020)

Inaugural dividend of €0.07 per share

First quarter 2021 earnings released: EPS €0.25 (vs €0.099 in 1Q 2020)

Full year 2020 earnings released: EPS €0.34 (vs €0.20 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €14.50

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

A/S Latvijas Juras medicinas centrs to Report First Half, 2021 Results between Aug 23, 2021 and Aug 27, 2021

New 90-day high: €7.95

Third quarter 2020 earnings released: EPS €0.26

New 90-day high - €16.90

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen